Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor | Zendy

Douglas B. Johnson | Zendy; Keith T. Flaherty | Zendy; Jeffrey S. Weber | Zendy; Jeffrey R. Infante | Zendy; Kevin B. Kim | Zendy; Richard Kefford | Zendy; Omid Hamid | Zendy; Lynn M. Schuchter | Zendy; Jonathan Cebon | Zendy; William H. Sharfman | Zendy; Robert R. McWilliams | Zendy; Mario Sznol | Zendy; Donald P. Lawrence | Zendy; Geoffrey T. Gibney | Zendy; Howard A. Burris | Zendy; Gerald S. Falchook | Zendy; Alain P. Algazi | Zendy; Karl D. Lewis | Zendy; Georgina V. Long | Zendy; Kiran Klaus Patel | Zendy; Nageatte Ibrahim | Zendy; Peng Sun | Zendy; Shonda M Little | Zendy; Elizabeth Cunningham | Zendy; Jeffrey A. Sosman | Zendy; Adil Daud | Zendy; René González | Zendy

Open Access

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF^V600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Author(s) -

Douglas B. Johnson,

Keith T. Flaherty,

Jeffrey S. Weber,

Jeffrey R. Infante,

Kevin B. Kim,

Richard Kefford,

Omid Hamid,

Lynn M. Schuchter,

Jonathan Cebon,

William H. Sharfman,

Robert R. McWilliams,

Mario Sznol,

Donald P. Lawrence,

Geoffrey T. Gibney,

Howard A. Burris,

Gerald S. Falchook,

Alain P. Algazi,

Karl D. Lewis,

Georgina V. Long,

Kiran Klaus Patel,

Nageatte Ibrahim,

Peng Sun,

Shonda M Little,

Elizabeth Cunningham,

Jeffrey A. Sosman,

Adil Daud,

René González

Publication year - 2014

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2014.57.3535

Subject(s) - dabrafenib , trametinib , medicine , hazard ratio , mek inhibitor , melanoma , oncology , regimen , progression free survival , phases of clinical research , combination therapy , clinical trial , vemurafenib , chemotherapy , cancer research , confidence interval , mapk/erk pathway , metastatic melanoma , kinase , biology , microbiology and biotechnology

Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research